In re: Entresto (Sacubitril/Valsartan) Patent Litigation

  1. August 13, 2024

    Entresto Release Delayed As Novartis Goes To Fed. Circ.

    A Delaware federal judge said Monday that Novartis is unlikely to prove that it's entitled to an injunction that would block MSN Pharmaceuticals from launching a generic version of its top-selling drug Entresto, but stayed the generic release briefly so Novartis could appeal to the Federal Circuit.

  2. February 08, 2024

    IP Forecast: 2nd Circ. To Hear TM Fight Over Whiskey Bottles

    The Second Circuit will consider whether a jury in the Southern District of New York was wrong to decide that the shape of bottles used by the Bulleit bourbon brand is distinctive enough to be protected by trademark law. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.

  3. July 07, 2023

    Delaware Judge Axes Novartis Patent On Heart Failure Drug

    A Delaware federal judge ruled Friday that a patent covering Entresto, a blockbuster heart failure drug made by Novartis, is invalid for lacking an adequate written description, handing a win to three Indian generics makers and leading Novartis to say it will appeal.

  4. September 28, 2022

    Novartis Gets Counterclaims Cut From Heart Drug Patent MDL

    A Delaware federal judge has thrown out declaratory judgment counterclaims lodged against Novartis by two generic-drug makers in multidistrict patent litigation over Novartis' heart medication Entresto, determining that the court lacks subject matter jurisdiction.